- Details
- Description
Bejescin (obinutuzumab) is an antineoplastic medicine containing obinutuzumab as its active ingredient. It is a monoclonal antibody that targets the CD20 protein found on the surface of B lymphocytes.
Indications: Obinutuzumab is used as part of specific treatment regimens for certain B-cell blood cancers, including chronic lymphocytic leukemia (CLL) and follicular lymphoma. Approved indications may vary depending on the country and the specific product labeling.
Dosage form: The medicine is generally supplied as a concentrate for preparation of a solution for intravenous infusion.
Administration: It is administered intravenously by a healthcare professional. The dosage and treatment schedule depend on the disease and the treatment regimen prescribed by the physician.
